News

NewsJune 2019

Update on the work of the BAP1-interest group (BIG) consortium published

The BAP1-interest group (BIG) consortium (http://www.bap1.org/) was formed by Professor Nick Hayward and Dr Mohamed Abdel-Rahman as a way to put the minds of many international professionals together to work on research about the BAP1-Tumour Predisposition Syndrome (BAP1-TPDS). The Consortium recently published its first paper in the Journal ofRead More

NewsSeptember 2018

Privacy Statement for Research on Melanoma carried out by the Section of Epidemiology and Biostatistics at the University of Leeds

The revised privacy statement detailing information for patients taking part in research studies carried out by the Section of Epidemiology and Biostatistics at the University of Leeds has been published. The statement can be found under the Info for Patients menu or by clicking the following link: Information forRead More

NewsAugust 2018

YouTive video: Professor Newton-Bishop talks about inherited risk of melanoma and sun exposure

Julia gave a talk at the Third UK MelanomaRead More

NewsMay 2018

Information of participants in the Leeds University study of melanoma in families

MREC 99/3/45 – Studies of Familial Melanoma In the years between 1989 and 2018, many individuals who have had melanoma or who have had melanoma in their families, took part in research led by Professor Julia Newton-Bishop. Research nurses Liz Pinney, Linda Whitaker and Susan Haynes worked with JuliaRead More

NewsAugust 2017

Risks of cancers related to smoking in families with CDKN2A mutations

High risk of tobacco-related cancers in CDKN2A mutation-positive melanoma families. Two research groups within GenoMEL have looked at the risk of cancers other than melanoma in families with inherited mutations in the p16 or CDKN2A gene: a group in Stockholm Sweden and another in Leiden, the Netherlands. WeRead More

NewsAugust 2017

Predictive Biomarker Research

A predictive biomarker is a test which provides information for medical teams and patients about how likely a particular treatment is to benefit that patient and or the risk of side effects. Using predictive biomarkers is an important part of the aim to deliver “personalised medicine”. That is, thatRead More